Close this search box.
Close this search box.

FDA Takes Unprecedented Step to Hire Experts in Metal-on-Metal Poisoning Crisis

By Rheingold Giuffra Ruffo & Plotkin LLP

In what could be called “too little, too late” for the impotent and corporately-influenced FDA, the orthopedic division has asked to impanel a medical-science committee to determine the implications of cobalt and chromium exposure to metal on metal implant recipients. Shockingly, it has come to light that in mid-2009 the very same FDA sent a non-approval letter to DePuy regarding their ASR resurfacing implant. This was private, yet patients still received metal on metal DePuy ASR total hip replacement implants until the mid-2010 recall. The FDA never warned these patients, some of which represent.

These studies have to be done at public expense even though Johnson & Johnson made millions of dollars from these implants and NEVER did any of their own pre-market testing or post-marketing surveillance with regard to metal diseases. Even worse, Johnson & Johnson continues to profit from this crisis by selling other implants to the revision victims. Thankfully, the Johnson & Johnson CEO has announced his resignation and the company has set aside billions of dollars for litigation.

As part of our representation, we provide our clients with more detailed information about the litigation. This appears in a separate, password protected area.

Related Posts

Paragard Bellwether Trial Update

The Paragard Multidistrict Litigation is moving forward after US District Court Judge issued the latest scheduling order concerning deadlines for discovery, including disclosure of experts

View Article